Cresilon Inc., a Brooklyn-based biotechnology company, has announced a strategic distribution agreement with McCarthy Vet to bring its revolutionary hemostatic gel VETIGEL to veterinary surgeons across Canada. The partnership marks Cresilon's first veterinary distribution agreement in the Canadian market, expanding access to the plant-based bleeding control technology that has already been used in more than 60,000 surgical procedures worldwide.
Revolutionary Hemostatic Technology Enters Canadian Market
VETIGEL, which debuted in 2021, represents a significant advancement in veterinary surgical care. The plant-based hemostatic gel instantly stops and controls bleeding through an innovative blend of plant polymers that form a mechanical barrier upon contact with bleeding tissue. Unlike traditional hemostatic agents, VETIGEL requires no preparation or special storage conditions and is supplied in a pre-filled syringe for immediate use.
"Our partnership with McCarthy Vet will help us provide more veterinary surgeons with an innovative hemostatic gel that significantly improves the standard of care for pets and animals," said VETIGEL National Sales Manager Brittany Boysen. "VETIGEL has been used by thousands of veterinarians around the world and helps veterinary clinics and animal hospitals save time, reduce operating costs, and improve patient outcomes."
Broad Surgical Applications Demonstrated
Since its launch, veterinary surgeons across North America, Europe, and Asia have increasingly adopted VETIGEL as their preferred hemostatic agent for both routine and complex procedures. The gel has proven effective across a wide range of surgical applications, including dental extractions, liver biopsies, tumor and mass removals, cleft palate repairs, and amputations.
The flowable nature of VETIGEL allows veterinary surgeons to control bleeding across various wound geometries and surgical sites. Once bleeding is controlled, the gel can be easily removed without disturbing the underlying clot or left in the body to resorb naturally, providing flexibility in surgical management.
Strategic Partnership with Established Distributor
McCarthy Vet, a family-owned and operated company that has exclusively served the Canadian veterinary community for over 60 years, will serve as the exclusive distributor for VETIGEL in Canada. The full-service veterinary marketing, supply and distribution company operates across all Canadian provinces, providing comprehensive coverage for veterinary professionals from coast to coast.
The collaboration reflects McCarthy Vet's ongoing commitment to bringing innovative products to market that offer meaningful clinical value, ease of use, and better outcomes for patients. As the company expands its portfolio through this new partnership, it continues to focus on delivering the solutions today's veterinary professionals need most.
Biocompatible and User-Friendly Design
VETIGEL's formulation addresses key concerns in veterinary surgery through its biocompatible, non-animal derived composition. The plant-based technology eliminates potential compatibility issues while providing reliable hemostatic performance. The product's ease of application, requiring no additional preparation, enhances its appeal among veterinary staff by saving time while ensuring high-quality patient care.
The hemostatic gel's ability to minimize the time animals spend under anesthesia represents a significant clinical advantage, potentially reducing surgical risks and improving overall patient outcomes. This efficiency gain, combined with the product's effectiveness in controlling bleeding, positions VETIGEL as an essential tool for modern veterinary practices.
Company Background and Innovation Focus
Cresilon, which was named to Fast Company's annual list of the World's Most Innovative Companies of 2024, ranking No. 1 in the medical devices category, develops, manufactures, and markets hemostatic medical devices utilizing proprietary hydrogel technology. The company's plant-based technology has revolutionized bleeding control standards by stopping bleeding in seconds.
The company's current and future product lines target trauma care, biosurgery, and animal health, with a mission focused on saving lives through innovative medical device solutions. The expansion into the Canadian veterinary market through the McCarthy Vet partnership represents a strategic step in broadening access to this life-saving technology.
